Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
BMC Infect Dis ; 22(1): 709, 2022 Aug 26.
Article in English | MEDLINE | ID: mdl-36028796

ABSTRACT

OBJECTIVE: We aimed to compare the changes in SARS-CoV-2 spike protein antibody titres based on age group and sex using paired blood sampling after vaccination in association with the presence of nucleocapsid protein antibody. METHODS: All participants were healthcare workers at Yao Municipal Hospital in Osaka who voluntarily provided peripheral blood samples (n = 636, men/women 151/485, mean age 45 years). We investigated the serial changes in SARS-CoV-2 spike protein antibody titres at 1 and 7 months after the second vaccination regarding their relationship with sex and age group. At 7 months, we also examined anti-nucleocapsid assays. Antibody titres were shown as logarithmic values and the differences were assessed using a paired or unpaired student's t-test as appropriate. RESULTS: Among participants younger than 30 years, the antibody titres of spike protein were significantly higher in women one (p = 0.005) and seven (p = 0.038) months after vaccination. However, among those aged 30-49 years, the antibody titres were not different between the sexes at either follow-up time point. In contrast, among those aged 50-59 years, between-sex differences in antibody titres were observed only at 7 months, which was associated with a significant reduction in men. A significant negative correlation was observed between the antibody titres for spike protein at both time points in participants with positive nucleocapsid protein antibody at 7 months (r = - 0.467, p = 0.043), although a significant positive correlation was observed in those with negative results (r = 0.645, p < 0.001), CONCLUSIONS: Between-sex differences in SARS-CoV-2 spike protein antibody titres by paired blood sampling at different time points after vaccination depended on age group. The presence of nucleocapsid protein antibody was associated with changes in spike protein antibody titres after vaccination.


Subject(s)
Antibodies, Viral , COVID-19 Vaccines , COVID-19 , Spike Glycoprotein, Coronavirus , Antibodies, Viral/blood , COVID-19/prevention & control , COVID-19 Vaccines/immunology , Female , Health Personnel , Humans , Male , Middle Aged , Nucleocapsid Proteins , SARS-CoV-2 , Spike Glycoprotein, Coronavirus/immunology , Vaccination
2.
BMJ Open ; 11(4): e046681, 2021 04 14.
Article in English | MEDLINE | ID: mdl-33853804

ABSTRACT

OBJECTIVES: Functional status assessments of activities of daily living may improve prognostic precision during initial diagnostic evaluations in young and middle-aged adults with cancer. However, the association between pretreatment functional status and survival in these patients is poorly understood. This study aimed to evaluate the prognostic value of functional status in young and middle-aged patients with cancer. DESIGN: Multicentre retrospective cohort study. SETTING: We used a cancer registry from Osaka Prefecture, Japan. The data were linked to administrative claims data from 35 hospitals in the same prefecture. PARTICIPANTS: Patients aged 18-69 years who received new diagnoses of gastric, colorectal or lung cancer between 2010 and 2014. MAIN OUTCOME MEASURE: Cox proportional hazards models of 5-year all-cause mortality were developed to examine the prognostic impact of pretreatment functional status, which was categorised into three levels of functional disability (none, moderate and severe) based on Barthel Index scores. The models controlled for age, sex, comorbidities, cancer stage and tumour histology. RESULTS: We analysed 12 134 patients. Higher mortality risks were significantly associated with moderate functional disability (adjusted HR 1.44 (95% CI 1.18 to 1.75), 1.35 (95% CI 1.08 to 1.68) and 1.74 (95% CI 1.50 to 2.03) in patients with gastric, colorectal and lung cancer, respectively) and severe functional disability (adjusted HR 3.56 (95% CI 2.81 to 4.51), 2.37 (95% CI 1.89 to 2.95) and 2.34 (95% CI 2.00 to 2.75) in patients with gastric, colorectal and lung cancer, respectively). CONCLUSION: Accounting for functional status at cancer diagnosis may improve the prediction of survival time in young and middle-aged adults with cancer. Functional status has potential applications in survival predictions and risk adjustments when analysing outcomes in patients with cancer.


Subject(s)
Colorectal Neoplasms , Lung Neoplasms , Activities of Daily Living , Adolescent , Adult , Aged , Colorectal Neoplasms/diagnosis , Functional Status , Humans , Japan/epidemiology , Middle Aged , Prognosis , Proportional Hazards Models , Retrospective Studies , Young Adult
3.
J Epidemiol ; 29(3): 110-115, 2019 Mar 05.
Article in English | MEDLINE | ID: mdl-30012908

ABSTRACT

BACKGROUND: The presence of comorbidities in cancer patients may influence treatment decisions and prognoses. This study aimed to examine the impact of comorbidities on overall survival in Japanese patients diagnosed with major solid tumors. METHODS: To obtain patient-level information on clinical conditions and vital status, we performed a record linkage of population-based cancer registry data from Osaka Prefecture, Japan and administrative data produced under the Diagnosis Procedure Combination (DPC) system. The study population comprised patients who received a primary diagnosis of gastric, colorectal, or lung cancer between 2010 and 2012 at any of five cancer centers. We employed the Charlson Comorbidity Index (CCI) score to quantify the impact of comorbidities on survival. The association between CCI score and survival for each cancer site was analyzed using Cox proportional hazards regression models for all-cause mortality, after adjusting for patient sex, age at cancer diagnosis, and cancer stage. RESULTS: A total of 2,609 patients with a median follow-up duration of 1,372 days were analyzed. The most frequent CCI score among the patients was 0 (77.7%), followed by 2 (14.3%). After adjusting for the covariates, we detected a significant association between CCI score and all-cause mortality. The hazard ratios per one-point increase in CCI score were 1.12 (95% confidence interval [CI], 1.02-1.23), 1.20 (95% CI, 1.08-1.34), and 1.14 (95% CI, 1.04-1.24) for gastric, colorectal, and lung cancer, respectively. CONCLUSIONS: Comorbidities have a negative prognostic impact on overall survival in cancer patients, and should be assessed as risk factors for mortality when reporting outcomes.


Subject(s)
Colorectal Neoplasms/epidemiology , Lung Neoplasms/epidemiology , Stomach Neoplasms/epidemiology , Aged , Aged, 80 and over , Colorectal Neoplasms/therapy , Comorbidity , Female , Follow-Up Studies , Humans , Japan/epidemiology , Lung Neoplasms/therapy , Male , Middle Aged , Prognosis , Risk Factors , Stomach Neoplasms/therapy , Survival Analysis
4.
Stud Health Technol Inform ; 245: 1379, 2017.
Article in English | MEDLINE | ID: mdl-29295458

ABSTRACT

The purpose of this study was to develop a prototype nursing observation support system using integrated nursing practice data with nursing records, prescription data, and nurse call logs. These data show that the present observation system has improved. The system has the potential to provide improved observations of chest symptoms and pain management.


Subject(s)
Medical Records Systems, Computerized , Nursing Records , Prescriptions , Humans , Pain Management
SELECTION OF CITATIONS
SEARCH DETAIL
...